Immune-Onc Therapeutics Announces Close of Series B Extension Financing, Bringing Total Round to $131 Million Thumbnail Image Read more about Immune-Onc Therapeutics Announces Close of Series B Extension Financing, Bringing Total Round to $131 Million
Diffuse Large B-Cell Lymphoma (DLBCL) Thumbnail Image Read more about Diffuse Large B-Cell Lymphoma (DLBCL)
Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009 Thumbnail Image Read more about Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009
Apply to the Influential Medicine Providing Access to Clinical Trials (IMPACT) Program Thumbnail Image Read more about Apply to the Influential Medicine Providing Access to Clinical Trials (IMPACT) Program
Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million ($57M USD) Thumbnail Image Read more about Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million ($57M USD)
X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia Thumbnail Image Read more about X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia
Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 and IRAKIMiD Degraders at the ASH Annual Meeting Thumbnail Image Read more about Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 and IRAKIMiD Degraders at the ASH Annual Meeting
Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research Thumbnail Image Read more about Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research
